Marshall Wace’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Marshall Wace’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43,952	Closed	-$82.2K	–	3352
2022 Q4	$82.2K	Buy	+43,952	New	+$110K	﹤0.01%	2811
2021 Q4	–	Sell	-111,547	Closed	-$542K	–	4420
2021 Q3	$542K	Sell	111,547 -140,051	-56%	-$772K	﹤0.01%	2341
2021 Q2	$1.72M	Buy	+251,598	New	+$2.03M	0.01%	1507
2020 Q1	–	Sell	-40,522	Closed	-$163K	–	2171
2019 Q4	$163K	Buy	+40,522	New	+$141K	﹤0.01%	1388
2018 Q1	–	Sell	-48,160	Closed	-$862K	–	665
2017 Q4	$862K	Buy	48,160 +4,173	+9%	+$87.1K	0.04%	255
2017 Q3	$1.1M	Buy	43,987 +4,749	+12%	+$111K	0.05%	218
2017 Q2	$942K	Buy	+39,238	New	+$867K	0.04%	198

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Marshall Wace's PRTK Position: Q1 2023 in Review

Marshall Wace sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 43,952 shares — an estimated $82.2K sold.

Marshall Wace first reported a position in PRTK in Q2 2017 and held it in 7 quarters. The position peaked at $1.72M in Q2 2021. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.

Marshall Wace reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Marshall Wace sold 43,952 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $82.2K.
Marshall Wace first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 7 quarters.
Marshall Wace's Paratek Pharmaceuticals, Inc. position peaked at $1.72M in Q2 2021.
63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.